SubHero Banner
Text

Rinvoq® (upadacitinib), Rinvoq LQ (upadacitinib) – New formulation approval, New/expanded indications

April 26, 2024 - The FDA approved a new oral solution formulation of Novartis’ Rinvoq (upadacitinib) (brand name Rinvoq LQ).

Download PDF

 

Text